The findings that either inhibition of EZH221 or activation of KDM6B, as reported here, was sufficient to induce neuroblastoma differentiation suggest that reducing H3K27me3 levels could be a differentiation-based therapeutic strategy in high-risk neuroblastoma, particularly in combination with RA or other differentiation-inducing agents. This evidence concerns the gene KDM6B and neuroblastoma.